Elevated Levels of Asymmetric Dimethylarginine in Chronic Heart Failure: A Pathophysiologic Link Between Oxygen Radical Load and Impaired Vasodilator Capacity and the Therapeutic Effect of Allopurinol
Key result
Allopurinol lowered ADMA concentration (P=0.02) and improved postischemic and endothelium-dependent vasodilation (both P<0.05) in patients with chronic heart failure.
Why the study?
Does allopurinol reduce reactive oxygen species and ADMA concentrations, and improve peripheral vasodilator capacity in patients with chronic heart failure?
Population
113 patients with chronic heart failure (CHF) and 26 controls
Design
RCT, double-blind
Authors
Discussion
Loading...
Member takes
Implication
Suggests allopurinol may enhance endothelial function in chronic HF; extends evidence linking oxidative stress to impaired vasodilation.
Study Design
Type
RCT (n=139)
Blinding
Double-blind
Structured PICO
Does allopurinol reduce reactive oxygen species and ADMA concentrations, and improve peripheral vasodilator capacity in patients with chronic heart failure?
P
Population
113 patients with chronic heart failure and 26 controls evaluated for ADMA levels and the therapeutic effect of allopurinol.
I
Intervention
Allopurinol
O
Outcome
Concentrations of reactive oxygen species (ROS), asymmetric dimethylarginine (ADMA), and peripheral vasodilator capacitysurrogate
Main Result
p-value: p=0.02
Allopurinol reduces ADMA levels and improves endothelial function in patients with chronic heart failure, highlighting a pathophysiologic link between oxidative stress and impaired vasodilation.
Cite This Study
Haehling et al. (2010) conducted an RCT in Chronic heart failure (n=139). Allopurinol vs. Placebo was evaluated on ADMA concentration (p=0.02). Allopurinol lowered ADMA concentration (P=0.02) and improved postischemic and endothelium-dependent vasodilation (both P<0.05) in patients with chronic heart failure.